Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
McKinsey
Argus Health
Covington
Cantor Fitzgerald
Medtronic

Generated: March 24, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR BORTEZOMIB

« Back to Dashboard

Clinical Trials for Bortezomib

Trial ID Title Status Sponsor Phase Summary
NCT00004002 PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma Completed National Cancer Institute (NCI) Phase 1 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of PS-341 in treating patients who have advanced solid tumors or lymphoma that have not responded to previous treatment.
NCT00004002 PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma Completed New York University School of Medicine Phase 1 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of PS-341 in treating patients who have advanced solid tumors or lymphoma that have not responded to previous treatment.
NCT00005064 PS-341 in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia in Blast Phase, or Myelodysplastic Syndrome Completed National Cancer Institute (NCI) Phase 1 Phase I trial to study the effectiveness of PS-341 in treating patients who have refractory or relapsed acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia in blast phase, or myelodysplastic syndrome. PS-341 may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth
NCT00006098 PS-341 in Treating Patients With Hematologic Cancer Completed National Cancer Institute (NCI) Phase 1 RATIONALE: PS-341 may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. PURPOSE: Phase I trial to study the effectiveness of PS-341 in treating patients who have hematologic cancer.
NCT00006098 PS-341 in Treating Patients With Hematologic Cancer Completed Memorial Sloan Kettering Cancer Center Phase 1 RATIONALE: PS-341 may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. PURPOSE: Phase I trial to study the effectiveness of PS-341 in treating patients who have hematologic cancer.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Bortezomib

Condition Name

Condition Name for Bortezomib
Intervention Trials
Multiple Myeloma 326
Lymphoma 49
Multiple Myeloma and Plasma Cell Neoplasm 26
Mantle Cell Lymphoma 25
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Bortezomib
Intervention Trials
Multiple Myeloma 441
Neoplasms, Plasma Cell 422
Lymphoma 147
Leukemia 66
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Bortezomib

Trials by Country

Trials by Country for Bortezomib
Location Trials
Germany 98
United Kingdom 96
France 76
Japan 72
Australia 48
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Bortezomib
Location Trials
California 141
New York 128
Texas 108
Massachusetts 104
Florida 99
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Bortezomib

Clinical Trial Phase

Clinical Trial Phase for Bortezomib
Clinical Trial Phase Trials
Phase 4 25
Phase 3 87
Phase 2/Phase 3 7
[disabled in preview] 529
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Bortezomib
Clinical Trial Phase Trials
Completed 341
Recruiting 163
Active, not recruiting 122
[disabled in preview] 139
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Bortezomib

Sponsor Name

Sponsor Name for Bortezomib
Sponsor Trials
National Cancer Institute (NCI) 200
Millennium Pharmaceuticals, Inc. 126
Celgene Corporation 35
[disabled in preview] 57
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Bortezomib
Sponsor Trials
Other 855
Industry 489
NIH 210
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Cantor Fitzgerald
Daiichi Sankyo
US Army
Argus Health
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.